Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2023 · 10-Q
Revenue$611.17K$611.17K+47.5% vs Q3 2022 Net Income-$1.06M-$1.06MN/M vs Q3 2022 EPS Diluted-$0.69-$0.69N/M vs Q3 2022 Operating Income-$1,146,685N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-187.6%+17.0 pt vs Q3 2022
Net margin-172.7%+21.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end